Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? by Strohl, M et al.
Abstract
Inflammatory bowel disease (IBD) is a lifelong, progres­
sive disease that has disabling impacts on patient’s lives. 
Given the complex nature of the diagnosis of IBD and 
its management there is consequently a large economic 
burden seen across all health care systems. Quality in­
dicators (QI) have been created to assess the different 
façades of disease management including structure, 
process and outcome components. Their development 
serves to provide a means to target and measure quality 
of care (QoC). Multiple different QI sets have been 
published in IBD, but all serve the same purpose of trying 
to achieve a standard of care that can be attained on a 
national and international level, since there is still a major 
variation in clinical practice. There have been many recent 
innovative developments that aim to improve QoC in 
IBD including telemedicine, home biomarker assessment 
and rapid access clinics. These are some of the novel 
advancements that have been shown to have great 
potential at improving QoC, while offloading some of the 
burden that IBD can have vis­a­vis emergency room visits 
and hospital admissions. The aim of the current review 
is to summarize and discuss available QI sets and recent 
developments in IBD care including telemedicine, and to 
give insight into how the utilization of these tools could 
benefit the QoC of IBD patients. Additionally, a treating­
to­target structure as well as evidence surrounding 
aggressive management directed at tighter disease 
control will be presented. 
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Core tip: The approach to diagnosis, follow up and 
management of inflammatory bowel disease (IBD) has 
undergone a major transformation in the past decade. 
Many different international quality indicators that span 
structure, process and outcome measures have been 
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developed. These serve as major targets in optimizing 
quality of care (QoC). New developments have been de­
signed to improve QoC including utilizing telemedicine, 
home biomarker testing and providing rapid access 
care to patients. Treating to target with proactive dis­
ease management guided by clinical history utilizing 
adjunctive biomarkers at the onset of IBD has been 
shown to improve objective outcomes. This will likely 
serve as the new favored treatment approach in many 
IBD centers across the globe. 
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INTRODUCTION
Inflammatory bowel disease (IBD) which primarily en­
compass ulcerative colitis (UC) and Crohn’s disease (CD) 
are chronic, progressive and disabling inflammatory 
diseases of the gastrointestinal (GI) tract, that in the 
uncontrolled setting often have disabling effects on an 
individual’s health and overall quality of life[1­3]. The pre­
valence and incidence of IBD is higher in North America 
and Western Europe compared to other parts of the 
world with data suggesting these rates are increasing[4,5]. 
Owing to IBD’s chronicity, varying degrees of severity and 
lifelong presence it contributes a large economic burden 
in all health care systems[1,6]. 
The treatment approach to managing IBD has 
evolved in the past decade undergoing a significant par­
adigm shift in philosophy. With the advent of early and 
routine use of biological therapies the manner in which 
IBD is diagnosed, managed and monitored has been 
in constant flux. The most recent advancements have 
been catalyzed by evidence suggesting that targeting 
symptom­based outcome parameters does not largely 
alter the natural course of IBD[7,8]. Inspired by evidence 
in other specialties, notably from the rheumatoid arthritis 
literature, the International Organization for the Study 
of Inflammatory Bowel Diseases (IOIBD) devised the 
STRIDE recommendations with the objective of providing 
a treat­to­target framework for IBD[9]. In parallel, ongoing 
evidence was amounting in the IBD literature regarding 
the association of endoscopic healing with improved 
clinical and long­term outcomes. This supports the notion 
of treating­to­target in IBD patients[10]. The STRIDE 
recommendations include targeting improvement in 
clinical and endoscopic outcomes and also incorporate 
patient reported outcome measures (PROM). These 
recommendations give rise to the potential of a greater 
impact on IBD compared to the former symptom derived 
scales including the Crohn’s Disease Activity Index 
(CDAI) or the partial Mayo Score. Virtually all newly de­
signed and recently published clinical trials in IBD have 
moved towards a similar structure focusing on complex 
outcomes encompassing clinical, endoscopic and PROM 
improvements[11].
A major challenge in the field of IBD lies in the 
large heterogeneity in clinical practice. This variation 
in everyday practice is seen in many domains of IBD 
management such as diagnostic testing, monitoring, 
therapeutic interventions and knowledge of preventative 
care recommendations[12­14]. As a result of the apparent 
differences in practice, a major interest was sparked in 
devising a standard set of measures to assess quality 
and provide a means to quantify quality of care (QoC). 
This occurred by developing quality indicators (QIs). 
QIs may be related to three components in health care: 
Structure, process and outcome parameters of care[15]. 
The goal is to utilize them to develop standards by which 
QoC can be assessed and measured[16].
In the following review, an overview of the various 
QIs that have been developed for IBD will be provided. 
Additionally, emerging evidence supporting the wide­
spread application of high QoC will be discussed along 
with some data on actual QI adherence at different 
centers and institutions. This will highlight how QIs can 
influence the level of care in IBD. Novel advancements 
which may have the potential to positively influence QoC 
will also be reviewed. Finally, the concept of treating­to­
target along with aggressive management directed at 
tighter disease control will be presented. 
QUALITY INDICATORS IN IBD
In general, QIs provide specific measurable elements of 
care for which there is evidence or consensus that can 
be applied to assess the QoC provided. This, thereore 
has the capacity to influence and improve QoC[17,18]. In 
2011 the American Gastrointestinal Association (AGA) 
published their clinical performance metrics that is used 
by federal health insurance providers to incentivize or 
penalize gastroenterologists managing IBD patients 
depending on the QoC they provide[19]. Given the limited 
scope of the AGA measures the Crohn’s and Colitis 
Foundation of America (CCFA) set out to develop, via a 
robust method, a set of top process and outcome rated 
QIs. The CCFA came out with its top­ten highly rated 
process and outcome related measures with the ultimate 
goal of having an impact on improving QoC in IBD[16]. 
Outside of the Unites States of America there have 
been multiple other published QI sets looking at various 
measures. In Spain a set of structure, process and 
outcome measures for quality of care was published 
using the Delphi consensus framework[20]. In Canada 
a similar set of QIs was published in 2014[21]. The 
Spanish and Canadian QI sets had the added layer of 
looking at structure metrics focusing on the importance 
of having a medical expert, a multidisciplinary team 
including a dedicated IBD nurse to assist in managing 
these complex cases. More recently in Canada, through 
the development of the Promoting Access and Care 
through Centers of Excellence (PACE) program a new 
set of structure, process and outcome QIs has been 
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developed[22]. The PACE program’s focus is to standardize 
QoC provided by physicians both in community hospitals 
and academic centers in an attempt to reduce the 
existing variation in practice. Unique to the process of 
developing these QIs was the involvement of actual IBD 
patients and IBD nurses in the QI selection procedure.
The British Society of Gastroenterology initially 
published guidelines to serve as their foundation for 
QoC in 2012[23]. On a similar theme with comparable 
components a QI set was published in Asia[24]. All these 
QIs have been established to accomplish the same and 
improve QoC. The difficulty of these approaches lies 
in finding the balance between a wide array of data 
captured and the practicality of the QI set to be used in 
clinical practice (Table 1).
VARIATION IN CLINICAL PRACTICE
Despite the development of multiple clinical practice 
guidelines in diagnosing and managing IBD from 
Europe[25­28] and North America[29,30] as well as the var­
ious of published quality measures in IBD highlighted 
above there is substantial heterogeneity in the practice of 
individual physicians. Feuerstein et al[31] retrospectively 
audited medical records from practices in academic, 
community and private centers in the United States to 
assess the adherence to quality measures published by 
the AGA. The authors discovered poor documentation 
of IBD quality measures by physicians regardless of 
practice settings. Specifically, a low proportion of phy­
sicians evaluated vaccination status with only 16.7% of 
patients evaluated for pneumococcal vaccine and 28.7% 
of patients evaluated for influenza vaccine. Additionally, 
only 25% of patients were assessed for bone loss. A 
survey of patients with CD and UC in the United States 
also demonstrated a large variation in practice between 
gastroenterologists (GI) in academic centers (GIA) vs 
private GI and other GIs[32]. In this survey CD patients 
seen by a GIA compared to private GIs had less use 
of 5­aminosalicylates and higher rates of biologic and 
immunomodulator uses (P < 0.001 for all). Furthermore, 
on multivariate analysis in GIA patients with CD there 
was less steroid use (OR = 0.84, 95%CI: 0.567­1.06), 
higher rates of influenza vaccination (OR = 1.33, 95%CI: 
1.15­1.53) and higher rates of clinical remission (OR = 
1.18, 95%CI: 1.02­1.37). Another study from Asia using 
a questionnaire devised from the AGA quality metrics 
showed a large variety in the deliverance of performance 
measures, again highlighting the heterogeneity in 
practice[24]. The European Crohn’s and Colitis Organization 
conducted a web based survey study of patients from 
27 different European Countries also showing signif­
icant impact on quality of life (QoL)[33]. 4990 patients 
responded to the survey of which 52% reported cortico­
steroid use within 12 mo, 71% experienced at least 2 
flares in a 2­year period and 44% of felt their lives were 
negatively impacted at times in between flares. Many 
reported on the negative impact the disease had with 
respect to work notably 44% reported losing their jobs or 
having to quit. Surprisingly, adequate access to care was 
only reported by 70% of those who responded to the 
survey with 53% of responders feeling they were unable 
to convey important information after consultation 
with a specialist. Clearly there are large differences in 
the practice of IBD between and even within a given 
health care system. Consequently, quality metrics and 
guidelines need to be reiterated and reinforced along 
with potential auditing measures to ensure that health 
professionals are upheld to appropriate standards.
EVIDENCE SURROUNDING QI 
APPLICATION
Intuitively one would stipulate that the more rigorously 
QIs are adhered to in IBD, the more one would expect to 
note an improvement in outcomes. Peña­Sánchez et al[34] 
conducted a retrospective population matched cohort 
study attempting to demonstrate a measureable outcome 
difference in patients exposed to a multidisciplinary IBD 
clinic (MIBDC) compared to controls who were not. The 
MIBDC accounted for some structural QIs such as having 
an IBD fellowship trained GI specialist, specialized IBD 
nurses, registered dieticians and a clinical psychologist. 
The goal set out by this unit was to ensure quality and 
continuity of care. Ultimately, what their study showed 
in the exposed UC group was lower rates of IBD related 
hospitalization (HR = 0.66, 95%CI: 0.49­0.89) and lower 
odds of corticosteroid dependence (OR = 0.39, 95%CI: 
0.15­0.98). In the entire exposed group compared to 
the un­exposed matched cohort they demonstrated a 
lower risk of IBD­related surgeries (HR = 0.78, 95%CI: 
0.61­0.99), lower rates of 5­ASA use (HR = 0.81, 
95%CI: 0.69­0.95), higher rates of immunomodulatory 
use (HR = 1.68, 95%CI: 1.42­1.99) and higher rates of 
biologic use (HR = 1.85, 95%CI: 1.52­2.27). This study 
effectively showed that an integrated medical care model 
in IBD was associated with better QoC in IBD patients 
compared to standard practice.
Law et al[35] performed a cohort study focusing on the 
impact of having exclusively subspecialized IBD trained 
physicians manage IBD patients admitted to hospital on 
short and long term clinical outcomes. They compared 
a cohort whereby inpatients were managed under gen­
eral gastroenterology care to ones managed under spe­
cialized IBD care. Looking at multiple in­hospital process 
and outcome QIs there were many similarities between 
the cohorts. The only statistically significant difference 
was that the specialized cohort ensured more objective 
disease assessment as evidenced by the higher rates of 
CRP testing at admission (82% vs 71%, P = 0.05) and 
discharge (25% vs 13%, P = 0.05). The cohort managed 
by specialized IBD care had increased frequency of high 
dose biologic therapy for induction (26% vs 9% P = 0.04, 
OR = 5.5, 95%CI: 1.3­23.17) and a higher proportion 
of patients in remission at 90 d (OR = 1.6, 95%CI: 
0.99­2.69). Although there was no difference in rates of 
surgery at 90 d, early surgery (within 30 d) was more 
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respect to the various published QIs. Recently, a study 
from Hungary was one of the first of its kind to report 
on its center’s performance with respect to well ac­
cepted structure, process and outcome QIs. Gonczi 
et al[36] vigorously evaluated whether or not their 
center was meeting the targeted QIs. In addition, they 
demonstrated effective implementation of a fast track 
open clinic concept centered on IBD care. This func­
commonly seen in the subspecialized IBD care group (OR 
= 2.73, 95%CI: 1.22­6.12). While both retrospective 
in nature these two studies support the notion that pro­
viding resources and specialized care geared at focusing 
on optimizing and maximizing QoC is associated with 
better outcomes in IBD patients. 
There is a scarcity of published data in the literature 
of IBD centers reporting on their performances with 
Strohl M et al . Quality of care in IBD
AGA CCFA PACE1 Spanish1 Asia
Structural QIs
IBD unit/clinic
Has access to healthcare professionals: pharmacist, ophthalmologist, rheumatologist, obstetrician and 
dermatologist
√
Has access to all of the following healthcare professionals: Dieticians, mental health worker/psychologist, 
stoma therapist
√
Has a dedicated IBD nurse. √ √
Has at least one gastroenterologist with specialized IBD training √
Has timely access to an Endoscopy Unit √ √
Has access to CT and MRI with at least one modality with enterography √ √
Has access to a GI radiologist and a GI histopathologist √ √
Has access to a surgical program that performs at least 10 Ileoanal pouch operations a year √
Has access to a fellowship trained colorectal surgeon √ √
Should be integrated in a hospital with an Emergency Department √ √
Process QIs
IBD type documented including disease location and severity √ √ √ √
Latent tuberculosis and Hepatitis B testing before anti-TNF therapy √ √ √ √ √
Appropriate initiation of steroid-sparing therapy √ √ √ √ √
Clostridium difficile testing during acute flares √ √ √ √ √
Venous thromboembolism prophylaxis is administered to patients according to national guidelines √ √ √ √ √
Cytomegalovirus testing via flexible sigmoidoscopy in steroid-refractory UC √ √ √
TPMT testing prior to thiopurine therapy √ √
Colectomy or close surveillance for low-grade dysplasia √ √ √
Surveillance colonoscopy for patients with colonic disease √ √ √
Screening and counseling for smoking cessation √ √ √ √ √
Vaccine education including pneumococcal and influenza √ √ √ √ √
Each IBD patient should be assigned one identifiable IBD specialist in charge of their care √ √
In patients with corticosteroid refractory IBD other induction therapies are recommended √
Medical salvage therapy and surgery are offered in UC inpatients failing to respond to intravenous 
corticosteroids within 5 d
√
The IBD Unit/clinic has a mechanism to screen for mental health issues √
Patients with IBD receiving maintenance immunosuppressive therapy are monitored with a blood count 
and liver profile every three months
√ √
Disease activity assessment is performed after initiating induction therapy √
The IBD Unit/clinic has a formal process for transfer of care from pediatric to adult √
IBD patients at risk for metabolic bone disease are assessed managed accordingly √ √ √ √
Calcium and Vitamin D are recommended in conjunction with systemic corticosteroids √
All HBsAg+ IBD patients should receive antiviral drugs while being treated with an anti-TNF drug √ √
Outcomes QIs
Proportion of patients with steroid-free clinical remission (CR) for > 12-mo period √ √
Proportion of patients currently taking prednisone (excluding those diagnosed within 112 d) √
Number of days per month/year lost from school/work attributable to IBD √
Number of days per year in the hospital attributable to IBD √ √
Number of emergency room visits per year for IBD √ √
Proportion of patients with malnutrition √
Proportion of patients with anemia √
Proportion of patients with normal disease-targeted health-related quality of life √
Proportion of patients currently taking narcotic analgesics √
Proportion of patients with nighttime BM’s or leakage √
Proportion of patients with incontinence in the last month √
Number of IBD-related surgeries per patient-year √
Validated assessment of patient adherence to management plan √
Table 1  Available quality indicators-set to assess the quality of care in inflammatory bowel disease
1Only selected QIs included. AGA: American Gastrointestinal Association; CCFA: Crohn’s and Colitis Foundation of America; MRI: Magnetic resonance 
imaging; PACE: Promoting access and care through centers of excellence; QI: Quality indicators; IBD: Inflammatory bowel disease; CT: Computed 
tomography; GI: Gastrointestinal; UC: Ulcerative colitis.
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tioned by providing immediate access for outpatient 
consultation within a median of 1 d following request. 
This fast track resource coupled with the IBD center 
applying and self­assessing adherence to QIs has a large 
potential on positively effecting QoC, optimizing resource 
utilization and possibly impacting disease outcomes. An 
important shortcoming to highlight while assessing QIs 
is that certain outcome QIs may differ depending on cen­
ter type. For instance, the outcomes at subspecialized 
referral centers for complex, refractory IBD cases are 
certainly different than community GI centers.
NOVEL ADVANCEMENTS WITH 
POTENTIAL TO INFLUENCE QOC
Optimizing patient care in IBD is a challenging process 
owing to the fact that achieving tight disease control 
and adequately monitoring patients requires substantial 
resource utilization, while requiring a significant com­
mitment from patients with respect to their time. 
This, coupled with the current demand to incorporate 
PROMs and assessing quality metrics to optimize QoC 
has sparked initiatives for reorganization of how care is 
delivered. Telemedicine, generally referred to as medicine 
practiced at a distance, has been present in healthcare 
in a variety of chronic diseases for nearly two decades[37] 
[Wootton, 2012 #61]. It provides a means to incorporate 
patient self­management by allowing patients to relay 
information to health care providers and to receive feed­
back[37]. Given the constraints and high resource usage 
in active IBD care, incorporating telemedicine appears 
promising. A systematic review and meta­analysis 
published in 2014 looked at all the published randomized 
control trials (RCTs) found that distance management 
significantly decreased clinic visits (mean difference of 
­1.08, 95%CI: ­1.6 to ­0.55) but did not affect relapse or
hospital admission rates[38]. One of the main limitations
of this analysis was the heterogeneity in the type of
distance management or forms of telemedicine used in
the included trials.
Many platforms for telemedicine in IBD exist but 
are limited to specific subsets of IBD patients[39]. A 
group from the Netherlands recognized this limitation 
which provided the foundation for the development of 
MyIBDcoach[40]. MyIBDcoach is the first telemedicine 
system that enables home monitoring for all subtypes 
of IBD. The platform may be used in academic and 
non­academic settings and looks at IBD facets, non­
IBD related aspects as well as other features including 
PROMS and quality metrics. De Jong et al[40] showed in 
their inception study that myIBDcoach was practical and 
well received by patients and health care providers. The 
same group then conducted a multicenter randomized 
control trial (RCT) to investigate the effect on care 
that their system may have compared to standard of 
care[41]. In the trial, they sought to compare outpatient 
visits; patient reported quality care and PROMs between 
the two groups. Overall the group that incorporated 
telemedicine via myIBDcoach had fewer outpatient visits, 
fewer telephone consultations, fewer admissions to hos­
pital as well as an increased adherence to medication. 
Importantly there were no significant differences in flare 
rates, rates of surgeries, emergency room visits or rates 
of corticosteroid use. Effectively via the well­designed 
myIBDcoach system the authors showed improved QoC, 
decreased resource utilization in terms of outpatient visits 
without demonstrating negative outcomes with respect 
to flares or complications of active disease.
Another major challenge with a large economic 
burden in the management of IBD relates to frequent 
emergency room (ER) visits. In a study from Manitoba, 
Canada, over a three­year period 76% of newly diag­
nosed IBD cases and 49% of patients already known 
to have IBD had at least 1 ER visit[42]. Many strategies 
have been utilized to decrease this burden in the ER 
and provide rapid access to the appropriate clinical 
care needed in times of active IBD. A pediatric study 
showed that increasing the availability of IBD specialists 
and specialized nurses via an electronic platform can 
decrease the frequency of ER visits[43]. Although in its 
infancy, a tertiary IBD center at McGill University in 
Montreal aimed to demonstrate improved quality of care 
by implementing a rapid access clinic (RAC)[44]. The RAC 
was structured by providing IBD patients followed at the 
clinic with an emergency contact email address, with a 
specific document explaining the pertinent symptoms 
that merit utilization of this access avenue. Each email 
was read and reviewed by a specialized IBD nurse or 
physician and depending on the situation a RAC visit 
was booked and the patient was seen. The preliminary 
data demonstrated a more optimized resource uti­
lization including frequent use of proactive biomarker 
measurements such as therapeutic drug monitoring, fecal 
calprotectin and C­reactive protein levels. The preliminary 
data also revealed that there was less need for computed 
tomography (CT), magnetic resonance imaging (MRI) 
and endoscopy. Notably, only a few patients in the RAC 
cohort required an ER visit within 30­90 d after accessing 
care. Clearly at high volume IBD centers this model of 
implementing a RAC may have significant potential to 
optimize resource utilization, decrease ER visits and 
improve QoC. 
IBD has a large psychosocial impact on patients 
with respect to their careers, productivity and social and 
intimate lives dramatically affecting their QoL[45,46]. The 
European Federation of Crohn’s and Ulcerative Colitis 
Associations published the results of a large survey to 
assess the impact of IBD from the patient’s perspective[45]. 
In total 4670 patients responded to a questionnaire 
that spanned 6 categories and contained 52 questions. 
48% of respondents felt that their life was significantly 
impacted by IBD even in times in remission. With re­
spect to work, 60% of surveyed patients felt stresses 
or pressured about taking time off when sick with 20% 
reporting being discriminated at workplace due to IBD. 
56% of people felt that IBD had affected their career 
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paths with 31% of individuals stating they either lost a 
job or quit a job due to their illness. 35% felt that their 
disease had prevented them from pursuing intimate re­
lationships. These negative impact patient centered mea­
sures on QoL were not incorporated into outcome metrics 
in many of the landmark IBD clinical trials. More recently 
however, this has changed and incorporating PROMs are 
an integral component in newly designed trials[11]. 
To address the issue of incorporating PROMs the IBD 
Disability index (IBD­DI) was developed as a tool that 
physicians can administer to evaluate the functional 
status of IBD patients[47]. The IBD­DI was validated for 
use in clinical trials showing high internal consistency, 
inter­observer reliability and construct validity[48]. The 
limitations of such a tool are its length and the fact 
that it was designed to be administered by health care 
professionals in the setting of clinical trials. Given the 
importance of QoL in managing IBD a recently developed 
tool known as the IBD­Disk was developed[49]. It is a self­
administered shortened adaptation of key components 
integrated in the IBD­DI tool. There are 10 items within 
the questionnaire with explanatory statements for each 
item. These are scored in a disc­shaped visual analog 
scale from 0 (absolutely disagree) to 10 (absolutely 
agree). This shortened IBD­Disk has the potential to be 
an integral PROM that can be used in day­to­day prac­
tice. Further work is needed to assess the tool’s operating 
characteristics and should compare the tool to the IBD­
DI. 
Within the realm of IBD management a major limi­
tation that exists in many heath care systems is the 
challenge in objectively determining disease activity. 
Endoscopy is ubiquitously considered the gold standard[50] 
but is expensive, invasive and utilizes significant health 
care resources thus imposing limitations when assessing 
IBD disease response during time of disease activity. 
Non­invasive markers biochemical and fecal markers 
such as CRP and FC are therefore often used in adjunct 
with clinical parameters in assessing disease response 
to therapy[51,52]. FC physiologically representing gut spe­
cific inflammation, has become more commonly imple­
mented as it has been shown to more accurately reflect 
endoscopic activity compared to CRP[51]. The drawback 
of conventionally available FC testing is that the test is 
enzyme­linked immunosorbent assay (ELISA) based 
and often is run in batches in hospitals. Consequently, 
there are often delays from obtaining the test and 
acting on the results which may result in unnecessary 
therapy escalation or utilizing endoscopy, which is more 
immediately available and reliable while waiting on the 
results of FC[53]. This limitation sparked the development 
of more rapidly available ELISA testing with the caveat 
that these tests also need to be performed in the hospital 
as point of care testing[54, 55]. Recognizing this drawback, 
a group out of Norway (CALPRO, Inc., Oslo, Norway) 
set out to develop a test that would allow FC testing 
directly by the patient as opposed to the point of care 
model which was simultaneously being developed[56]. 
The same group developed the CalproSmart that allows 
FC testing to be performed by the patients themselves 
at home with the results available within minutes[53]. 
Vinding et al[53] compared the performance of the 
CalproSmart tool to conventional FC ELISA testing 
with exciting results. The correlation coefficient was 
0.685 with sensitivity, specificity, positive predictive 
value and negative predictive values of 82%, 85%, 
47% and 97% respectively using a cut­off of 150 μg/g. 
The positive likelihood ratio (LR+) at this cut­off was 
5.51 while the negative likelihood ratio (LR­) was 0.21. 
Extrapolating from the performance of the CalproSmart 
home assessment at the cut­off used (150 μg/g) it 
appears to be more suitable in correlating the absence 
of disease activity rather than predicting disease activity. 
Nevertheless, this kind of tool empowers the patient, can 
be integrated in eHealth and telemedicine systems and 
provides a means of potentially identifying early relapse 
in IBD. 
TREATING TO TARGET IN IBD
There has been a major shift in the management of IBD 
in the past decade. Classically, IBD was managed in a 
step­up approach escalating therapy if it were felt to be 
indicated based primarily on symptom driven scores[57]. 
However, the step­up paradigm of management has 
many limitations. Firstly, it puts individuals at a higher 
risk of prolonged corticosteroid exposure and the as­
sociated increased adverse events[58]. Secondly, due to 
time constraints inherent in a step­up framework there 
is a delay in delivering more effective therapy in high 
risk patients[59]. Lastly, this model depends on symp­
tom derived scales for disease activity which poorly 
correlate to endoscopic disease activity[59]. Evidence 
has been conclusive in the rheumatoid arthritis (RA) 
literature whereby treatment strategies that utilize 
aggressive upfront strategies treating­to­target, as op­
posed to conventional step up therapy have resulted 
in better outcomes[60]. In RA management strategies 
are employed that modify treatments aggressively and 
proactively in response to changes in validated outcome 
measures indicative of active disease[61]. 
Motivated by the rheumatology field and other chron­
ic diseases such as diabetes mellitus that use a model 
that actively guide therapy based on specific targets, a 
treat­to­target paradigm was devised for IBD. Initially 
Bouguen et al[59] proposed a framework to guide treating­
to­target in Crohn’s disease. In this model during the 
initial treatment phase, disease response should be 
actively followed using clinical symptoms, biochemical 
markers adjunctively and ultimately targeting mucosal 
healing. If there is a lack of response, initial therapy 
should be optimized accordingly with consideration of 
adding adjunctive medication. If, despite this, treatment 
targets are not achieved then a class switch should 
be considered. While the CD specific framework was 
developed IOIBD were simultaneously working on 
developing IBD related treat­to­target recommendations. 
The IOIBD published the STRIDE recommendations 
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encompassing targets to strive for in both UC and CD[9]. 
These recommendations encompassed specific targets 
that should be the main focus when managing IBD. 
EVIDENCE SUPPORTING TIGHTER 
CONTROL LEADING TO BETTER 
OUTCOME
Prior to the innovation and development of treating­
to­target, the concept of early combined immuno­
suppression (ECI) emerged. This treatment strategy was 
conceived due to the evidence of shortcomings in how 
IBD was being managed at the time using a step­up 
approach. Both the TOP­DOWN[62] [D’Haens, 2008 #78] 
and SONIC[63] were well designed RCTs for treatment 
naïve Crohn’s patients that showed superiority in the ECI 
group compared to conventional therapy. Note that both 
these trials utilized symptoms derived primary outcome 
measures: Harvey Bradshaw Index (HBI) ≤ 4 for SONIC 
and Crohn’s disease activity index (CDAI) < 150 in TOP­
DOWN. Despite the results of these two landmark trials, 
the common practice at the time remained limited to 
the step­up model. Subsequently the REACT trial was 
designed to validate the generalizability of algorithm­
based therapy notably in the practice of community GIs 
in existing IBD patients[64]. The REACT trial randomized 
two groups to either the algorithm­based or conventional 
therapy. Disease activity was assessed at 4 or 12 wk post 
initial corticosteroid therapy with remission being defined 
by a HBI ≤ 4. In the algorithm­based group disease was 
reassessed every 12 wk and therapy was optimized if 
clinical remission was not attained. Ultimately, although 
the study did not demonstrate statistically different 
rates of corticosteroid free clinical remission at 12 mo, 
the trial did show that at 24 mo the composite outcome 
rate of surgery, hospital admissions and or serious 
disease related complications was lower in the algorithm­
based group while no differences in serious drug related 
adverse events was noted. 
Novel concepts of treating­to­target combined with 
a top­down approach were the inspirations for designing 
the CALM study[65]. This study was a RCT aimed at in­
vestigating the efficacy and safety of two treatment 
algorithms in achieving mucosal healing in early CD. 
One arm, the tight control group, was modelled on a 
treat­to­target framework with therapy decisions de­
termined on the basis of pre­specified treatment failure 
criteria compromised of clinical symptoms (CDAI) and 
biomarkers of inflammation (CRP and FC). Comparatively, 
the clinical management group’s treatment plan was 
solely based on clinical symptoms (CDAI). A few of the 
exclusion criteria included current or previous biologic or 
immunomodulator exposure, fibrostenotic disease and 
fistulizing disease (only perianal fistula not draining at 
enrolment were included). The primary endpoint was the 
proportion of patients with mucosal healing, defined by 
a Crohn’s disease endoscopic index of severity (CDEIS) 
< 4 and no deep ulcers 48 wk after randomization. 
With respect to the primary outcome 46% of patients 
in the tight control group achieved mucosal healing 
compared to 30% in the clinical management group (P 
= 0.01). In terms of secondary outcomes, statistically 
significant differences were observed between the two 
groups in deep remission, biological remission and 
steroid­free remission at every follow up visit. There 
were no significant differences in adverse events nor 
serious adverse events between the two arms. The 
CALM study is a pivotal trial in IBD as it is the first to 
show superiority of incorporating objective markers of 
inflammation in addition to clinical symptoms in a treat­
to­target framework that leads to better outcomes in 
IBD compared to conventional clinical management 
approaches. 
CONCLUSION
The field of IBD is rapidly changing with major shifts 
in the philosophy of management. Meeting structure, 
process and outcome QIs and keeping the patient at 
the center of focus is key in achieving good QoC. Much 
advancement in the diagnosis, follow­up and access to 
care are being made with promising results. 
It is becoming increasingly clear, particularly looking 
at the CALM and REACT trials, aggressive and proactive 
management guided by treating­to­target and actively 
reassessing a patient’s evolution is a promising path to 
improve long term related IBD disease outcomes. Mea­
suring multiple QIs and adjusting the treatment plan 
accordingly will help to improve the level of care and 
optimize patient access, monitoring and outcomes of 
patients with IBD. 
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